Metástasis

Novocure Announces 26 Presentations at American Association for Cancer Research (AACR) Annual Meeting 2021 Suggesting Broad Applicability of Tumor Treating Fields

Retrieved on: 
Friday, April 9, 2021
Oncology, Medical devices, Health, Other Health, Radiology, Biotechnology, Cancer, Clinical medicine, Medicine, Oncology, Cancer treatments, Gynaecological cancer, Cancer pathology, Metástasis, Alternating electric field therapy, Brain metastasis, Chemotherapy, Ovarian cancer

Novocure (NASDAQ: NVCR) today announced 26 presentations on Tumor Treating Fields suggesting broad applicability of Tumor Treating Fields at the American Association for Cancer Research (AACR) Annual Meeting 2021, held virtually from April 10 to April 15, 2021.

Key Points: 
  • Novocure (NASDAQ: NVCR) today announced 26 presentations on Tumor Treating Fields suggesting broad applicability of Tumor Treating Fields at the American Association for Cancer Research (AACR) Annual Meeting 2021, held virtually from April 10 to April 15, 2021.
  • Research spanning seven solid tumor types confirms the anti-mitotic effect of Tumor Treating Fields and further explores downstream effects to identify optimal use of Tumor Treating Fields, including the role of Tumor Treating Fields-induced immunogenic cell death.
  • H. Ben Atya (Tumor Biology)
    (Poster #: 3071) A method for infratentorial structures segmentation for tumor treating fields treatment planning.
  • Novocure has ongoing clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.

Palleon Pharmaceuticals Presents Data Suggesting Role of Hypersialylation in Metastatic Melanoma Patients’ Resistance to PD1 Inhibitors

Retrieved on: 
Friday, April 9, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Medicine, Medical specialties, Clinical medicine, Oncology, Cancer, Melanoma, Immune checkpoint, Metástasis, BRAF, Tumor microenvironment, Cancer immunotherapy

The research, conducted in collaboration with Massachusetts General Hospital, used Palleons HYDRA technology to quantify immunosuppressive sialoglycans of melanoma tumor samples.

Key Points: 
  • The research, conducted in collaboration with Massachusetts General Hospital, used Palleons HYDRA technology to quantify immunosuppressive sialoglycans of melanoma tumor samples.
  • Hypersialylation of tumor cell-surface glycans is known to correlate with poor cancer prognosis, potentially by enabling tumors to evade immune detection.
  • In this study, researchers aimed to evaluate how hypersialylation might contribute to a cancers resistance to immune checkpoint therapies.
  • Additionally, these signatures did not correlate with other common melanoma biomarkers such as BRAF-mutation, liver metastases, or TILs, suggesting that hypersialylation may impact response to PD1 inhibitors independently of these pathways.

 Volastra Therapeutics Co-founder Samuel Bakhoum to Deliver Plenary Presentation at American Association for Cancer Research Annual Meeting 2021

Retrieved on: 
Thursday, April 8, 2021
Biotechnology, Pharmaceutical, Health, Oncology, Branches of biology, Oncology, American Association for Cancer Research, Cancer, Chromosome instability, Clinical medicine, Health, Plenary, Metástasis

Volastra Therapeutics today announced that Co-founder Samuel Bakhoum, M.D., Ph.D., and Scientific Advisory Board Member David Pellman, M.D., will both deliver plenary presentations at the April session of the American Association for Cancer Research (AACR) Annual Meeting 2021.

Key Points: 
  • Volastra Therapeutics today announced that Co-founder Samuel Bakhoum, M.D., Ph.D., and Scientific Advisory Board Member David Pellman, M.D., will both deliver plenary presentations at the April session of the American Association for Cancer Research (AACR) Annual Meeting 2021.
  • The plenary session, titled Mechanisms, Impact, and Exploitation of Cancer Chromosomal Instability, is dedicated to exploring a key driver of tumor progression.
  • Volastra is building on this groundbreaking work into the biology of chromosomal instability, which will be shared throughout the plenary session, to develop new therapies for metastatic cancer.
  • Its importance to the future of cancer treatment is underscored by AACRs decision to devote a leading plenary session to the topic, said Dr. Bakhoum.

FDA Approves Trodelvy®, the First Treatment for Metastatic Triple-Negative Breast Cancer Shown to Improve Progression-Free Survival and Overall Survival

Retrieved on: 
Thursday, April 8, 2021
Oncology, Medical Supplies, Health, Hospitals, Pharmaceutical, Biotechnology, Chemical compounds, Cancer, Breast cancer, Clinical medicine, Breakthrough therapy, Protein kinase inhibitors, Metastatic breast cancer, Brain metastasis, Metástasis, Triple-negative breast cancer, CDK inhibitor

Prior to the FDA approval of Trodelvy, patients with previously treated metastatic TNBC had few treatment options in this high unmet-need setting.

Key Points: 
  • Prior to the FDA approval of Trodelvy, patients with previously treated metastatic TNBC had few treatment options in this high unmet-need setting.
  • Trodelvy is also being developed as an investigational treatment for metastatic urothelial cancer, hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER 2-) metastatic breast cancer and metastatic non-small cell lung cancer.
  • TNBC is an aggressive type of breast cancer, accounting for approximately 15% of all breast cancers.
  • Additional efficacy measures included PFS for the full population (all patients with and without brain metastases) and overall survival (OS).

Volastra Therapeutics Extends Seed Financing to $44 Million to Advance Drug Discovery Programs to Prevent Cancer Metastasis

Retrieved on: 
Tuesday, April 6, 2021
Oncology, Professional services, Health, Finance, Clinical trials, Pharmaceutical, Biotechnology, Oncology, Cancer, Medical specialties, Health, Metástasis, Treatment of cancer, Prostate cancer, Metastatic breast cancer, Cancer survival rates

In the U.S. alone, more than 350,000 people a year are diagnosed with metastatic cancer.

Key Points: 
  • In the U.S. alone, more than 350,000 people a year are diagnosed with metastatic cancer.
  • Less than a third respond to targeted or immuno-therapies, making metastasis one of the most pressing unsolved challenges in cancer.
  • Volastra Therapeutics is pioneering novel approaches to halt or prevent cancer metastasis, one of the major unsolved challenges in cancer treatment.
  • Based in West Harlem, N.Y., Volastra is committed to improving outcomes for people living with cancer.

Volastra Therapeutics Partners with Microsoft to Advance Metastatic Cancer Research

Retrieved on: 
Tuesday, April 6, 2021
Biotechnology, Health, Science, Research, Oncology, Oncology, Cancer, Health, Metástasis, Treatment of cancer, Medicine, Clinical medicine

Volastra Therapeutics today announced it will collaborate with Microsoft to develop tools that help detect drivers of cancer metastasis.

Key Points: 
  • Volastra Therapeutics today announced it will collaborate with Microsoft to develop tools that help detect drivers of cancer metastasis.
  • We are excited to work with Microsoft to apply data science to the challenges of cancer research.
  • The collaboration with Volastra will lead to potential advances in the development of therapies to prevent and treat cancer metastasis.
  • Volastra Therapeutics is pioneering novel approaches to halt or prevent cancer metastasis, one of the major unsolved challenges in cancer treatment.

Cello Therapeutics’ Platelet Membrane-Coated Nanoparticles Offer a Novel Platform for the Delivery of Immunotherapy in Cancer Treatment

Retrieved on: 
Thursday, April 1, 2021
Cancer, Medicine, Clinical medicine, Oncology, Cancer pathology, Tumor, Tumor microenvironment, Metástasis, Treatment of cancer, Cancer treatments, Cancer research, Metastatic breast cancer

In a new study published today inNature Communications, Cello Therapeutics shows how semisynthetic nanoparticles coated in platelet membrane can effectively inhibit tumor growth and metastasis in multiple mouse models of solid tumors.

Key Points: 
  • In a new study published today inNature Communications, Cello Therapeutics shows how semisynthetic nanoparticles coated in platelet membrane can effectively inhibit tumor growth and metastasis in multiple mouse models of solid tumors.
  • Previous studies have shown that platelets naturally bind to both cancer cells and components of the tumor microenvironment.
  • Localized intratumoral injection of PNP-R848 effectively eliminated or inhibited tumor growth in two separate mouse models of cancer.
  • About Cello Therapeutics Inc.: Founded in 2016 in San Diego, CA, Cello is an emerging biotechnology company focused on developing novel nanoparticle delivery platforms for cancer treatment.

Biotechs Working on Potential Preventive Measures and Cancer Treatments

Retrieved on: 
Tuesday, March 30, 2021
Clinical medicine, Medicine, Cancer, Oncology, Breast cancer, Treatment of cancer, Ovarian cancer, Melanoma, Metástasis, Veliparib, Adjuvant therapy

Jeremy Sobotta, CEO at Perimeter Medical, stated , "our novel technology is addressing an unmet need in breast cancer surgery.

Key Points: 
  • Jeremy Sobotta, CEO at Perimeter Medical, stated , "our novel technology is addressing an unmet need in breast cancer surgery.
  • This tool has the potential to change the future of cancer treatments and reduce the likelihood of a second operation.
  • Syndax Pharmaceuticals (NASDAQ:SNDX) announced last April that the biotech company was in the early stages of a potential blood cancer treatment .
  • The company has been involved in several clinical trials for products that target breast cancer, metastatic melanoma, lung cancer, solid tumors, ovarian cancer, and beyond.

Biotechs Working on Potential Preventive Measures and Cancer Treatments

Retrieved on: 
Tuesday, March 30, 2021
Clinical medicine, Medicine, Cancer, Oncology, Breast cancer, Treatment of cancer, Ovarian cancer, Melanoma, Metástasis, Veliparib, Adjuvant therapy

Jeremy Sobotta, CEO at Perimeter Medical, stated , "our novel technology is addressing an unmet need in breast cancer surgery.

Key Points: 
  • Jeremy Sobotta, CEO at Perimeter Medical, stated , "our novel technology is addressing an unmet need in breast cancer surgery.
  • This tool has the potential to change the future of cancer treatments and reduce the likelihood of a second operation.
  • Syndax Pharmaceuticals (NASDAQ:SNDX) announced last April that the biotech company was in the early stages of a potential blood cancer treatment .
  • The company has been involved in several clinical trials for products that target breast cancer, metastatic melanoma, lung cancer, solid tumors, ovarian cancer, and beyond.

Study Shows Guardant360 Liquid Biopsy Predicts Response to Pembrolizumab-Based Immunotherapy in Patients with Metastatic Non-Small Cell Lung Cancer

Retrieved on: 
Friday, March 26, 2021
Oncology, Health, Hospitals, Genetics, Managed care, Pharmaceutical, Biotechnology, Clinical medicine, Medicine, Health care, Lung cancer, Breakthrough therapy, Orphan drugs, Biopsy, Interventional radiology, Non-small-cell lung carcinoma, Cancer, Liquid biopsy, Metástasis

For patients with metastatic non-small cell lung cancer (mNSCLC), not harboring an actionable mutation, immunotherapy is often recommended for first-line treatment.

Key Points: 
  • For patients with metastatic non-small cell lung cancer (mNSCLC), not harboring an actionable mutation, immunotherapy is often recommended for first-line treatment.
  • The Guardant360 test is used to guide treatment in metastatic non-small cell lung cancer as the number of treatment-relevant genomic alterations continues to grow.
  • The Guardant360 test is broadly covered by Medicare for use across the vast majority of advanced solid tumors, including patients with metastatic non-small cell lung cancer.
  • Guardant Health has commercially launched liquid biopsy-based Guardant360, Guardant360 CDx, and GuardantOMNI tests for advanced stage cancer patients, and Guardant Reveal test for early-stage cancer patients.